Published in J Clin Invest on April 19, 2010
Understanding type 1 diabetes through genetics: advances and prospects. Nat Rev Genet (2011) 1.64
Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation. J Immunol (2011) 1.10
On the perils of poor editing: regulation of peptide loading by HLA-DQ and H2-A molecules associated with celiac disease and type 1 diabetes. Expert Rev Mol Med (2012) 0.95
Cell-surface MHC density profiling reveals instability of autoimmunity-associated HLA. J Clin Invest (2014) 0.90
Proficiency testing of human leukocyte antigen-DR and human leukocyte antigen-DQ genetic risk assessment for type 1 diabetes using dried blood spots. J Diabetes Sci Technol (2010) 0.89
Generation of hematopoietic humanized mice in the newborn BALB/c-Rag2null Il2rγnull mouse model: a multivariable optimization approach. Clin Immunol (2011) 0.85
Assessment of CD4+ T cell responses to glutamic acid decarboxylase 65 using DQ8 tetramers reveals a pathogenic role of GAD65 121-140 and GAD65 250-266 in T1D development. PLoS One (2014) 0.85
Posttranslational modifications of proteins in type 1 diabetes: the next step in finding the cure? Diabetes (2012) 0.84
Differential binding of pyruvate dehydrogenase complex-E2 epitopes by DRB1*08:01 and DRB1*11:01 Is predicted by their structural motifs and correlates with disease risk. J Immunol (2013) 0.82
Understanding TR binding to pMHC complexes: how does a TR scan many pMHC complexes yet preferentially bind to one. PLoS One (2011) 0.79
DynaDom: structure-based prediction of T cell receptor inter-domain and T cell receptor-peptide-MHC (class I) association angles. BMC Struct Biol (2017) 0.75
The role of islet antigen presenting cells and the presentation of insulin in the initiation of autoimmune diabetes in the NOD mouse. Immunol Rev (2016) 0.75
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Phaser crystallographic software. J Appl Crystallogr (2007) 108.34
PHENIX: building new software for automated crystallographic structure determination. Acta Crystallogr D Biol Crystallogr (2002) 53.61
WHAT IF: a molecular modeling and drug design program. J Mol Graph (1990) 24.35
Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet (2007) 19.04
HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature (1987) 10.70
Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med (1978) 7.97
Role of diffusion in ligand binding to macromolecules and cell-bound receptors. Biophys J (1982) 4.99
Rapid, electrostatically assisted association of proteins. Nat Struct Biol (1996) 4.72
Use of peptide libraries to map the substrate specificity of a peptide-modifying enzyme: a 13 residue consensus peptide specifies biotinylation in Escherichia coli. Biotechnology (N Y) (1993) 4.70
The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science (1999) 3.23
Rational design of faster associating and tighter binding protein complexes. Nat Struct Biol (2000) 3.03
Histocompatibility (HL-A) antigens associated with systemic lupus erythematosus. A possible genetic predisposition to disease. N Engl J Med (1971) 2.69
Progression of autoimmune diabetes driven by avidity maturation of a T-cell population. Nature (2000) 2.39
Conformational equilibria in -and -chymotrypsin. The energetics and importance of the salt bridge. J Mol Biol (1972) 2.07
Structure of a covalently stabilized complex of a human alphabeta T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1. EMBO J (2000) 2.00
A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science (2000) 1.84
Susceptible MHC alleles, not background genes, select an autoimmune T cell reactivity. J Clin Invest (2003) 1.80
Structural basis of peptide binding and presentation by the type I diabetes-associated MHC class II molecule of NOD mice. Immunity (2000) 1.77
Crystal structures of mouse CD1d-iGb3 complex and its cognate Valpha14 T cell receptor suggest a model for dual recognition of foreign and self glycolipids. J Mol Biol (2008) 1.72
Alphabeta T cell receptor interactions with syngeneic and allogeneic ligands: affinity measurements and crystallization. Proc Natl Acad Sci U S A (1997) 1.67
Natural peptides selected by diabetogenic DQ8 and murine I-A(g7) molecules show common sequence specificity. J Clin Invest (2005) 1.60
Restricted islet-cell reactive T cell repertoire of early pancreatic islet infiltrates in NOD mice. Proc Natl Acad Sci U S A (2002) 1.49
The I-Ag7 MHC class II molecule linked to murine diabetes is a promiscuous peptide binder. J Immunol (2000) 1.36
The role of HLA-DQ8 beta57 polymorphism in the anti-gluten T-cell response in coeliac disease. Nature (2008) 1.16
Binding of conserved islet peptides by human and murine MHC class II molecules associated with susceptibility to type I diabetes. Eur J Immunol (2000) 1.11
Evidence for shared recognition of a peptide ligand by a diverse panel of non-obese diabetic mice-derived, islet-specific, diabetogenic T cell clones. Int Immunol (2002) 1.06
Prevention of diabetes in NOD mice by a mutated I-Ab transgene. Diabetes (1998) 0.94
Monoclonal T cells identified in early NOD islet infiltrates. Immunity (1996) 0.94
Thymic positive selection and peripheral activation of islet antigen-specific T cells: separation of two diabetogenic steps by an I-A(g7) class II MHC beta-chain mutant. J Immunol (1998) 0.92
The biology of NKT cells. Annu Rev Immunol (2007) 14.43
Antibody recognition of a highly conserved influenza virus epitope. Science (2009) 11.26
Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature (2011) 11.07
Structure and receptor specificity of the hemagglutinin from an H5N1 influenza virus. Science (2006) 10.04
HIV vaccine design and the neutralizing antibody problem. Nat Immunol (2004) 9.48
Interleukin-10 determines viral clearance or persistence in vivo. Nat Med (2006) 8.01
The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120. J Virol (2002) 7.82
Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections. Nature (2005) 7.72
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol (2006) 7.57
Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. Proc Natl Acad Sci U S A (2004) 7.55
Lysosomal glycosphingolipid recognition by NKT cells. Science (2004) 7.31
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science (2004) 6.70
Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science (2003) 6.68
Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol (2005) 6.17
Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science (2010) 6.10
The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science (2011) 6.01
Structural genomics of the Thermotoga maritima proteome implemented in a high-throughput structure determination pipeline. Proc Natl Acad Sci U S A (2002) 6.00
A highly conserved neutralizing epitope on group 2 influenza A viruses. Science (2011) 5.66
Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature (2012) 5.63
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J Virol (2003) 5.59
Crystal structure of a soluble cleaved HIV-1 envelope trimer. Science (2013) 5.53
Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nat Immunol (2006) 5.51
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science (2011) 5.44
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol (2005) 4.71
A thymic precursor to the NK T cell lineage. Science (2002) 4.66
Cryo-EM structure of a fully glycosylated soluble cleaved HIV-1 envelope trimer. Science (2013) 4.61
Coeliac disease. Lancet (2003) 4.47
Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science (2011) 4.42
Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity (2004) 4.36
Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science (2007) 4.35
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity (2005) 4.26
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog (2013) 4.23
New world bats harbor diverse influenza A viruses. PLoS Pathog (2013) 4.10
Protein production and purification. Nat Methods (2008) 3.97
Crystal structure of human toll-like receptor 3 (TLR3) ectodomain. Science (2005) 3.72
Distinct functional lineages of human V(alpha)24 natural killer T cells. J Exp Med (2002) 3.70
Antibody vs. HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A (2005) 3.57
Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55
Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science (2012) 3.53
Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature (2008) 3.47
Highly conserved protective epitopes on influenza B viruses. Science (2012) 3.47
Exploration of uncharted regions of the protein universe. PLoS Biol (2009) 3.41
Plague bacteria target immune cells during infection. Science (2005) 3.32
Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure (2004) 3.31
A Blueprint for HIV Vaccine Discovery. Cell Host Microbe (2012) 3.27
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A (2010) 3.24
A dynamic knockout reveals that conformational fluctuations influence the chemical step of enzyme catalysis. Science (2011) 3.19
Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nat Immunol (2005) 3.12
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat Struct Mol Biol (2013) 3.11
Clonal selection of helper T cells is determined by an affinity threshold with no further skewing of TCR binding properties. Immunity (2004) 3.06
Crystal structure of a bacterial cocaine esterase. Nat Struct Biol (2002) 3.06
Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteins. Science (2003) 3.05
Recent avian H5N1 viruses exhibit increased propensity for acquiring human receptor specificity. J Mol Biol (2008) 3.00
Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci U S A (2013) 2.96
Characterization of the early stages of thymic NKT cell development. J Exp Med (2005) 2.84
Glycan microarray technologies: tools to survey host specificity of influenza viruses. Nat Rev Microbiol (2006) 2.83
Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol (2004) 2.80
HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol (2009) 2.80
Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci U S A (2010) 2.77
Intrinsic functional dysregulation of CD4 T cells occurs rapidly following persistent viral infection. J Virol (2005) 2.75
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans. PLoS Pathog (2013) 2.66
Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol (2008) 2.63
T cell activation by lipopeptide antigens. Science (2004) 2.59
Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A (2005) 2.50
Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature (2012) 2.44
Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc Natl Acad Sci U S A (2011) 2.38
A modified alpha-galactosyl ceramide for staining and stimulating natural killer T cells. J Immunol Methods (2006) 2.36
Three-dimensional structural view of the central metabolic network of Thermotoga maritima. Science (2009) 2.33
Integration of genetic and immunological insights into a model of celiac disease pathogenesis. Annu Rev Immunol (2011) 2.31
Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe (2008) 2.30
Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A (2012) 2.27
XtalPred: a web server for prediction of protein crystallizability. Bioinformatics (2007) 2.26
The Bacillus subtilis quorum-sensing molecule CSF contributes to intestinal homeostasis via OCTN2, a host cell membrane transporter. Cell Host Microbe (2007) 2.26
The molecular interaction of CAR and JAML recruits the central cell signal transducer PI3K. Science (2010) 2.26
Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 A. Nat Immunol (2003) 2.20
Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. J Exp Med (2005) 2.18
Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing. Nat Biotechnol (2012) 2.14
Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J Virol (2008) 2.14
Structural basis of steroid hormone perception by the receptor kinase BRI1. Nature (2011) 2.12
Structural basis of TLR5-flagellin recognition and signaling. Science (2012) 2.10
Contrasting IgG structures reveal extreme asymmetry and flexibility. J Mol Biol (2002) 2.10
Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation. Proc Natl Acad Sci U S A (2013) 2.10
Hepatitis C virus E2 envelope glycoprotein core structure. Science (2013) 2.06
Outcome of a workshop on applications of protein models in biomedical research. Structure (2009) 2.05
Effects of lipid chain lengths in alpha-galactosylceramides on cytokine release by natural killer T cells. J Am Chem Soc (2004) 2.05
Multiple defects in antigen presentation and T cell development by mice expressing cytoplasmic tail-truncated CD1d. Nat Immunol (2001) 2.04
Reprogramming of CTLs into natural killer-like cells in celiac disease. J Exp Med (2006) 2.03
Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS (2007) 2.03
The junctional adhesion molecule JAML is a costimulatory receptor for epithelial gammadelta T cell activation. Science (2010) 2.02
The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J Virol (2004) 2.02
The specificity of TCR/pMHC interaction. Curr Opin Immunol (2002) 1.99
The CD100 receptor interacts with its plexin B2 ligand to regulate epidermal γδ T cell function. Immunity (2012) 1.98